Literature DB >> 10455470

Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass?

P Gosse1, V Jullien, P Jarnier, P Lemetayer, J Clementy.   

Abstract

OBJECTIVES: It has been suggested that hypertensives at high risk of cardiovascular complications can be identified on the basis of their left ventricular mass as determined echographically. However, there is as yet a lack of consensus on the mode of indexation (body surface area, height, height 2.7) of left ventricular mass (LVM), and on the cut-off values for definition of left ventricular hypertrophy (LVH). The main objective of this study is to test the influence of the different modes of indexation for LVM on the prevalence of LVH in a population of never treated hypertensive patients on the basis of cut-offs for LVM based upon its relationship with ambulatory blood pressure (BP) measurement.
METHODS: A population of 363 untreated hypertensives was investigated using a standardised procedure. The men and women were analysed separately. We studied the relationship between mean daytime ambulatory systolic BP and LVM and calculated the LVM cut-off for a BP of 135 mm Hg using three different methods of indexation. On the basis of these criteria, the population was divided into those with and those without LVH.
RESULTS: The prevalence of LVH was found to be higher when LVM was indexed to height2.7 (50.4%) or height (50.1%). Prevalence was lowest when LVM was indexed to body surface area (48.2%), which tended to minimise the hypertrophy in obese individuals. Only indexation by height 2.7 fully compensates for relationships between height and ventricular mass in this population.
CONCLUSIONS: Indexing LVM to height 2.7 thus appeared to give a more sensitive estimate of LVH by eliminating the influence of growth. Cut-offs of 47 g/m2.7 in women and 53 g/m2.7 in men corresponded to a cardiovascular risk indicated by a daytime systolic BP >/=135 mm Hg.

Entities:  

Mesh:

Year:  1999        PMID: 10455470     DOI: 10.1038/sj.jhh.1000885

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice.

Authors:  Anderson C Armstrong; Samuel Gidding; Ola Gjesdal; Colin Wu; David A Bluemke; João A C Lima
Journal:  JACC Cardiovasc Imaging       Date:  2012-08

2.  The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.

Authors:  Alain J Nordmann; Murray Krahn; Alexander G Logan; Gary Naglie; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Echocardiographic partition values and prevalence of left ventricular hypertrophy in hypertensive Nigerians.

Authors:  Adewole A Adebiyi; Okechukwu S Ogah; Akinyemi Aje; Dike B Ojji; Adedeji K Adebayo; Olulola O Oladapo; Ayodele O Falase
Journal:  BMC Med Imaging       Date:  2006-08-29       Impact factor: 1.930

4.  Indexation of left ventricular mass to predict adverse clinical outcomes in pre-dialysis patients with chronic kidney disease: KoreaN cohort study of the outcome in patients with chronic kidney disease.

Authors:  Sung Woo Lee; Hyang Ki Min; Dong-Wan Chae; Kook-Hwan Oh; Curie Ahn; Wookyung Chung; Joongyub Lee; Yong-Soo Kim; Su Ah Sung
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

5.  Age-specific diastolic dysfunction improves prediction of symptomatic heart failure by Stage B heart failure.

Authors:  Jennifer M Coller; Fei Fei Gong; Michele McGrady; Michael V Jelinek; Julian M Castro; Umberto Boffa; Louise Shiel; Danny Liew; Simon Stewart; Henry Krum; Christopher M Reid; David L Prior; Duncan J Campbell
Journal:  ESC Heart Fail       Date:  2019-05-15

6.  Left Ventricular Diastolic and Systolic Functions in Patients with Hypothyroidism.

Authors:  Rina Tafarshiku; Michael Y Henein; Venera Berisha-Muharremi; Ibadete Bytyçi; Pranvera Ibrahimi; Afrim Poniku; Shpend Elezi; Gani Bajraktari
Journal:  Medicina (Kaunas)       Date:  2020-10-07       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.